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ABSTRACT 
Background: The interplay between tumor site, ultraviolet radiation (UVR) exposure, 
genetic factors and various epidemiological parameters of cutaneous melanoma is complex. 
In this thesis, we aimed to investigate the impact of detailed body site of the primary tumor 
beyond the conventional and strictly anatomic division of the head-neck, trunk, upper- and 
lower extremities, focusing on body site division according to UVR exposure patterns in 
relation to risk, outcome and other factors. 
Methods: We retrospectively reviewed medical records of patients with cutaneous melanoma 
to obtain detailed site information of the primary tumor (studies I–IV). We then entered 
detailed site on a three-dimensional anatomic model in a computer software, and classified 
body areas according to UVR exposure patterns, visibility upon skin self-examination, and 
anatomic classifications more detailed than the ICD (International Classification of Diseases) 
codes. Through linkage with regional and/or national registers, we obtained data on incidence 
and survival, as well as established confounders and (when applicable) losses to follow-up. 
We also reviewed medical records for sentinel node location and -status (study I), and 
performed PCR and pyrosequencing for mutation analysis of proto-oncogenes BRAF and 
NRAS (study IV). 
Results: Trunk melanoma was associated with multiple but not uncommon sentinel node 
locations, compared to extremity melanoma. Multiple or uncommon sentinel node locations 
were not found to explain the association between trunk melanoma and reduced patient 
survival (study I). Melanomas assigned to intermittent UVR exposure patterns according to 
detailed anatomic site of the primary tumor displayed a higher incidence increase in the 
Stockholm-Gotland region during the past decades compared to melanomas on sites with 
assigned chronic UVR exposure patterns (study II). Site-assigned highly intermittent UVR 
patterns and poorly visible sites upon skin self-examination were associated with reduced 
patient survival compared to chronically UVR exposed and easily visible sites, respectively 
(study III). Intermittently UVR exposed sites were associated with BRAF mutations, and 
chronically UVR exposed sites with NRAS mutations (study IV). 
Conclusions: Primary tumor sites with assigned intermittent UVR exposure patterns are 
presumably related to the incidence increase as well as reduced patient survival and genetic 
BRAF mutations of cutaneous melanoma, whereas sites assigned to chronic UVR exposure 
patterns contribute less to the incidence increase, are prognostically more favorable, and 
predominantly display NRAS mutations. Multiple or uncommon sentinel node locations do 
not explain the adverse prognosis of trunk melanoma. 
Key words: Melanoma, Body site, Ultraviolet radiation exposure, Genetic factors, Incidence, 
Time trends, Sentinel node, Survival 
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1 INTRODUCTION 
The incidence of cutaneous melanoma in Sweden has increased fourfold from 1976 to 2015 
(1). Ultraviolet radiation (UVR) exposure is the main risk factor of melanoma and changing 
UVR exposure patterns are thus regarded as drivers of the incidence increase. Intermittent 
UVR exposure is believed to contribute more than chronic UVR exposure. These exposure 
patterns have also been linked to different genetic mutations. Unfortunately, UVR exposures 
are difficult to quantify as each individual’s exposure is a mix between intermittent and 
chronic UVR over a lifetime.  
Scientific evidence is scarce on how different UVR exposure patterns cause and interact with 
other factors in cutaneous melanoma, and how a further incidence increase should be 
prevented. In fact, there are no signs of a decreasing melanoma incidence in Sweden despite 
repeated public health efforts to promote prevention, with an average annual percentage 
increase of about 5% from 2005 to 2015, and a mortality rate of 4† to 7‡ per 100,000 
inhabitants (2015) (1). Hence, the societal costs of cutaneous melanoma are large, spanning 
from the suffering of patients and those close to them to economic costs of direct (healthcare) 
and indirect (productivity losses) nature. 
Primary tumor site as classified in the International Classification of Diseases (ICD) is an 
independent prognostic factor for localized melanoma, and is often used as a proxy variable 
of UVR exposure patterns. However, it is a rather crude, and strictly anatomic, classification. 
A more detailed anatomic classification of primary body site may be of additional value 
regarding prognostic prediction. Also, a classification of the primary tumor site based on 
common skin coverage, or lack thereof, by clothes may better capture UVR exposure 
patterns. 
In this thesis, we aimed to evaluate detailed body site of the primary tumor, mainly as a proxy 
variable for UVR exposure patterns but also from a purely anatomic perspective, in relation 
to (1) the incidence increase, (2) genetic factors, (3) sentinel node location and (4) prognosis 
of cutaneous melanoma. 
 
 
 
 
 
 
†  Women 
‡  Men 
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2 BACKGROUND 
2.1 INCIDENCE AND SURVIVAL 
Incidence 
From 1976 to 2015, the incidence (age-standardized to the Swedish population 2000 in 
parentheses) of melanoma has increased from 9.1 (9.4) to 39.3 (36.3) per 100,000 inhabitants 
for women and 8.6 (9.6) to 41.3 (41.6) for men (Figure 2.1.1) (1). Today, melanoma is the 
fifth and sixth most common malignancy in Sweden among women and men, respectively, 
with 3,951 new cases diagnosed in 2015, and a cumulative probability of 2.3–2.4% of 
developing melanoma before the age of 75 years (1). 
Changing UVR exposure patterns have been suggested as the main driver of this increase, 
although early diagnosis and a diagnostic drift (2), where borderline lesions are increasingly 
classified as malignant, cannot be excluded as contributory factors. 
 
 
Figure 2.1.1 Incidence (number of tumors per 100,000 inhabitants) and mortality of 
malignant melanoma in Sweden by sex (1). Compiled from data from the Swedish 
Cancer Register and Cause-of-Death Register. 
 
Aims have been set to reduce the incidence to levels below that of the year 2000 by 2020 (3), 
but despite primary prevention efforts there are no indications of a stabilization. In fact, a 
comparison showed continued increases in all age groups from 25–30 years of age and older, 
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from 1993–1995 to 2013–2015 (Figures 2.1.2–2.1.3) (1). 
 
 
Figure 2.1.2. Incidence (number of tumors per 100,000 inhabitants) of malignant 
melanoma in Sweden among women (1). Compiled from data from the Swedish Cancer 
Register. 
 
 
Figure 2.1.3. Incidence (number of tumors per 100,000 inhabitants) of malignant 
melanoma in Sweden among men (1). Compiled from data from the Swedish Cancer 
Register.  
  5 
Survival 
Mortality rates in Sweden due to melanoma have been more stable from 1976 to 2015 
compared to the incidence increase, but the trend is still that of an increasing mortality in the 
population, with a rate of 2.0 deaths per 100,000 inhabitants for women and 2.9 for men in 
1976, and 3.9 and 6.6. in 2015, respectively (1). However, between 2012 and 2015 the death 
rates have remained largely unchanged (Figure 2.1.1). Whereas increasing age at diagnosis 
and increased numbers of thick lesions may be contributory factors to the long-term mortality 
trend (4), it will be interesting to follow the continued development of mortality rates in the 
context of the new oncologic therapies introduced for stage IV melanoma during the past 
years. 
The likelihood of survival is high among individuals with stage I melanoma (see section 2.4.1 
for stage definitions), and low among those with stage IV melanoma, with a 5-year survival 
of <20% among the latter (Figures 2.1.4–2.1.5) (5). Among young individuals, death due to 
melanoma constitutes 8% of all tumor-related deaths (6). 
 
Figure 2.1.4. Melanoma-specific survival proportion over time (years) among patients 
with stage I melanoma (5). From the Swedish Melanoma Register April 2012. 
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Figure 2.1.5. Melanoma-specific survival proportion over time (years) among patients 
with clinical stage II–IV melanoma (5). From the Swedish Melanoma Register April 
2012. 
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2.2 RISK FACTORS 
2.2.1 Environmental 
Ultraviolet radiation (UVR) exposure is necessary for life on Earth and for our physical 
health and psychological well-being. At the same time, UVR radiation is also a class I 
carcinogen, with a potential to cause cancer comparable to the use of tobacco, and the main 
environmental risk factor for cutaneous melanoma (7,8). The statement specifically concerns 
i) solar radiation, ii) UVR including UVA, UVB and UVC, and iii) UV-emitting devices. 
Solar radiation and UVR 
Of the UVR emitted from the sun, UVC (wavelength 100–280 nm) does not penetrate the 
ozone layer of the stratosphere, whereas UVA (>315–400 nm) constitutes the larger part 
(95%) of UVR that reaches the earth, and UVB (>280–315 nm) a lesser part (5%) (8,9). 
The intensity of UVR exposure is determined by the time of the day, season, latitude, 
altitude, surface reflection, cloud formation, the ozone layer, and degree of pollution (8). 
The most intense exposure is emitted between 11:00 and 15:00 (10). 
UV intensity can be quantified using the UV index (11). It is determined by the maximum 
UVR intensity during a 24-hour period, and varies significantly by latitude, season and time 
of the day as well as weather conditions and the ozone layer. Levels 1–2 are considered low, 
3–5 moderate, 6–7 high, 8–10 very high, and ≥11 extreme. In brief, low levels are generally 
considered safe with regard to outdoor activities, whereas higher levels warrant increasing 
sun protective measures. In Sweden, the UV index in the summer is moderate to high in clear 
weather, whereas in Southern Europe levels are very high, and in Thailand extreme (12). 
Tanning devices 
The most commonly used tanning devices among the public almost exclusively emit UVA 
(>>95%), but also a small amount of UVB (<<5%) (8,13). Exposure to artificial UVR from 
sunbeds at a young age (< 35 years) has been clearly associated with the development of 
cutaneous melanoma (HR 1.75; 95% CI 1.34–2.26) in a large meta-analysis (13). Further, 
evidence does not favor prophylactic use of these devices in order to reduce sun-induced 
damage from later solar radiation (14). 
UVR exposure patterns 
Although the relationship between UVR exposure and melanoma development is complex, 
two main patterns have been proposed to describe UVR exposure: intermittent and chronic 
UVR exposure patterns. 
Comparison of studies on intermittent UVR exposure is complicated by the varying 
definitions and methods to quantify this exposure, but cumulative evidence supports the 
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importance of intermittent UVR exposure as a risk factor for cutaneous melanoma (15–25). 
Intermittent UVR exposure is often referred to with regard to situations when skin without 
recent exposure is exposed to intense UVR exposure and thus prone to sunburn, which has 
also been linked to melanoma development (19–24,26–34). Examples of intermittent UVR 
exposure behavior in the literature include vacations on sunny latitudes, active sunbathing, 
beach sports, use of sunbeds and previous sunburns. Further, primary tumor sites on the trunk 
or extremities have been used as proxy variables of intermittent UVR exposure (see section 
2.2.2). 
Chronic UVR exposure has instead been used with reference to more long-term or 
continuous exposures that are related to the development of melanization and a protective 
tan, and cumulative sun-induced damage. Examples include outdoor occupational UVR 
exposure, primary tumor site on the head and neck (see section 2.2.2), and signs of 
cumulative sun-induced damage (marked/severe elastosis). The evidence with regard to 
chronic UVR exposure and the risk of developing melanoma is less clear than that of 
intermittent UVR exposure, but points toward a neutral (23) or even protective (24,25,35) 
association. 
Genetic mutations 
Genetic “fingerprint” or signature mutations such as cyclobutane pyrimidine dimer 
formation have been associated with UVR exposure (9,13). Interestingly, the BRAF and 
NRAS mutations commonly found in cutaneous melanomas do not display this fingerprint 
pattern. However, a linkage to UVR exposure is indicated by other UV-related mechanisms 
(36), the distribution of these mutations by primary tumor site (see section 2.2.2), and the 
absence (37–40) or presence (38) of signs of cumulative sun-induced damage (38), 
respectively. BRAF mutations have also been associated with sunburn in animal experiments 
(41). 
2.2.2 Constitutional 
Genotype, phenotype and family 
The most commonly mutated gene in hereditary melanoma, CDKN2A, entails a very high 
risk (60-fold risk increase) of developing cutaneous melanoma among family members that 
are mutation carriers (42). Individuals belonging to families with familial melanoma without 
mutated CDKN2A are also at increased risk of developing melanoma, as are those that do not 
classify into the latter category but have (at least) one first-degree relative diagnosed with 
melanoma (42,43). 
A third category of risk individuals are those with sensitive pigmentation traits with regard 
to skin color and skin type according to Fitzpatrick, hair and eye color (43), and a high 
number (44) (>50–100) and/or large size (>5 mm) of melanocytic nevi (42). MC1R 
alterations are common among individuals with a fair skin color that burns easily and tans 
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poorly, and red hair, but the gene may also contribute to the risk of melanoma through 
pigment-independent pathways (45). 
Sex and age 
Melanoma is very uncommon until puberty, and increases progressively thereafter (see 
Figures 2.1.2–2.1.3) (1), with a median age at diagnosis of 64 years for men, and 60 for 
women (4). However, UVR exposure during childhood is a risk factor for cutaneous 
melanoma (32,46), supporting the concept of a latency phase between exposure and disease 
development. It has also been demonstrated that UVR exposure in childhood is associated 
with the development of nevi (47), and that the distribution of nevi among children correlates 
with the site distribution of melanoma among young adults (48). 
Anatomic site 
The most common cutaneous melanoma site according to the ICD code is the trunk among 
men, and the lower extremities among women. Meanwhile, melanoma on head and neck sites 
is mainly related to older age (Figure 2.2.2) (5,49). Melanomas on the trunk are often 
associated with nevi (50–54). Melanomas of unknown, and non-cutaneous (mucosal and 
ocular) body sites are not covered in this thesis. 
The incidence increase of the past decades has occurred mainly for trunk and extremity 
melanomas, whereas melanomas on the head and neck have increased less in most reports 
(55–61). Further, upper extremity melanomas have increased among men during recent years 
(4). 
Study-specific aspects 
Given that UVR exposure is the main risk factor for sporadic cutaneous melanoma, it is 
believed that the increased incidence on different body sites reflects changes in UVR 
exposure behavior among the public. Specifically, trunk and extremity sites are often used as 
crude proxy variables for intermittent UVR exposure, and head and neck sites for chronic 
UVR exposure. However, no previous studies have been designed to specifically evaluate the 
association between detailed anatomic site classified by intermittent vs. chronic UVR 
exposure in relation to incidence trends using an established UVR exposure model (→study 
II). 
In a similar fashion, the preponderance of BRAF mutations among trunk and extremity 
melanomas (37,62–65) and sites without signs of cumulative sun-induced damage (37–40), 
and NRAS on sites with signs of cumulative sun-induced damage (38), has suggested that 
BRAF mutations may be associated with intermittent UVR exposure, and NRAS mutations 
with chronic UVR exposure, but the hypothesis has not been evaluated in a more detailed 
UVR exposure model (→study IV). 
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Figure 2.2.1. Body site, sex and age of patients diagnosed with cutaneous melanoma 
1990−2008 (5). From the Swedish Melanoma Register 2012-03-15. 
 
2.2.3 Psychology/lifestyle 
Psychology 
The psychological driving components of UVR exposure include well-being and esthetic 
incentives (6). A recent study from 2015 among Swedish high-school students showed that 
their sun exposure behavior is highly affected by esthetic ideals favoring a tanned complexion 
(6). Of particular concern is that 18–32% reported that a “good tan” is desirable even if it 
entails a slight sunburn. This coheres with findings from international studies, where a strong 
“tan-seeking behavior” (66), poor sun-protective behavior and more frequent sunburn 
episodes (67) have been observed in Sweden compared to other countries. 
Lifestyle 
During the past decades, travel to sunny destinations has become increasingly available to 
the public. This increase is demonstrated below in a graph compiled from flight data from the 
Swedish Aviation Authority (Figure 2.2.3) (68). 
Although causality cannot be determined between flight data and UVR exposure/melanoma 
development, it is feasible to hypothesize that increased charter travel to sunny destinations 
and the related sudden change of latitude and high-intensity intermittent UVR exposure is 
associated with the increased incidence of melanoma during the past decades. The 
identification of post-secondary education (compared to compulsory education only) as a 
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risk factors for melanoma (1) may also cohere with this hypothesis. 
 
 
Figure 2.2.3. Number of arriving and departing passengers in scheduled and non-
scheduled international traffic at Swedish airports 1972 to 2012. Compiled from data 
from the Swedish Aviation Authority (68). 
 
2.2.4 Other risk factors 
Other risk factors for developing cutaneous melanoma include a history of previous 
melanoma or other skin cancer (42). 
2.3 PROTECTIVE FACTORS 
Shadow, clothing, and the use of sunscreen (69) are regarded as protective factors with 
regard to the risk of developing cutaneous melanoma. However, the use of sunscreen can 
prolong UVR exposure (70,71), which may at least partially explain the results of studies 
showing a lack of protective, or even adverse, associations between the use of sunscreen and 
melanoma. 
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2.4 PROGNOSTIC FACTORS 
2.4.1 Stage and TNM classification 
The likelihood of melanoma survival depends largely on stage and TNM classification, with 
great differences between these categories (see Figures 2.1.4–2.1.5) (5). Stage and TNM 
category can be determined on a clinical (Table 2.4.1) or histopathological basis, of which 
the latter includes a subdivision of stage III melanomas into the stages IIIA, B and C based on 
a detailed classification of lymph nodes in the N category (N1a–N3) obtained through 
sentinel node biopsy or lymph node dissection (72,73). 
For macroscopically localized melanoma (i.e. no evidence of metastases upon clinical or 
radiological evaluation), tumor thickness, ulceration, mitotic rate and sentinel node status (74) 
are strong independent prognostic factors. Of these, sentinel lymph node status is the 
strongest one, since it identifies patients with and without microscopic loco-regional spread. 
 
Table 2.4.1. Clinical stage and TNM classification (72,73). 
 Clinical 
 stage 
   T 
Thickness 
(mm) 
Ulceration 
Mitoses 
(n / mm2) 
N M 
  0 Tis n/a n/a n/a N0 M0 
  IA T1a ≤1.0  no* 0* N0 M0 
  IB T1b ≤1.0 yes* ≥1* N0 M0 
 T2a 1.01–2.0 no n/a N0 M0 
  IIA T2b 1.01–2.0 yes n/a N0 M0 
 T3a 1.01–2.0 no n/a N0 M0 
  IIB T3b 1.01–2.0 yes n/a N0 M0 
 T4a 1.01–2.0 no n/a N0 M0 
  IIC T4b 1.01–2.0 yes n/a N0 M0 
  III T† n/a n/a n/a N>0   M0 
  IV T† n/a n/a n/a N‡ M1 
†  All T categories. 
‡  All N categories. 
* T1a and b classification based on the presence or absence of ulceration or mitoses. 
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T ─ Tumor 
The T category is determined by tumor thickness, ulceration and mitotic rate. 
N ─ Nodal 
The N category is determined by the number of metastatic lymph glands and the metastatic 
burden as defined by the presence of macroscopic, microscopic or satellite/in-transit 
metastases. Microscopic metastases are evaluated using sentinel lymph node biopsy (SLNB) 
[A] (75). In addition to being a diagnostic tool, procedure-related melanoma-specific survival 
benefits (compared to nodal observation) have been shown among intermediate thickness 
(1.2–3.5 mm) melanomas (76). Individuals with nodal metastases are classified as having 
stage III melanoma. 
[A] SLNB is a staging procedure for clinical stage IB and II, and selected cases of high-risk 
stage IA, melanoma. The procedure is based on the postulation that the first lymphatic 
node(s) that drains lymphatic fluid from the primary tumor is a gate-keeper (sentinel) of 
metastatic spread, i.e. the absence of tumor cells in a sentinel lymph node indicates localized 
disease whereas the presence of tumor cells indicates loco-regional and possible further 
spread. 
In brief, a radiocolloid and blue dye are injected around the primary tumor and followed to 
one or several lymph nodes in the first adjacent regional lymph node basin or (less 
commonly) other node locations, where the node(s) are removed and undergo 
histopathological evaluation. Based on the latter, sentinel node status is determined as 
positive (at least one pathological lymph node) or negative (disease-free lymph nodes only). 
M ─ Metastasis 
The M category is determined by the presence or absence of distant metastases. Individuals 
with distant metastases (M1) are classified as having stage IV melanoma. M1 melanomas 
can be subdivided into the categories M1a–c based on the metastatic site and lactate 
dehydrogenase (LDH) levels. 
2.4.2 Other prognostic factors 
Patient factors 
Prognostic patient factors include sex (77–82), age (78–81), socioeconomic status (83), 
cohabitation (84), and comorbidities (85).  
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Anatomic site 
Anatomic site of the primary tumor according to the ICD classification is an independent 
prognostic factor (86–88), with a worse prognosis for the trunk (82,86,87) and scalp (89–91) 
compared to the face and extremities. The mechanism behind this is unknown. Further, 
evidence is conflicting with regard to the importance of detailed anatomic site division in 
relation to patient survival. 
Study-specific aspects 
Since melanomas on trunk sites display lymphatic drainage to uncommon (see section 4.4 for 
definition) (92–105) and multiple (106–112) sentinel node locations more often than those 
on extremity sites, it has been hypothesized that these could be related the reduced survival 
among individuals with trunk melanoma (86,113–116). However, previous studies have 
suffered from limited power or evaluated short-term prognostic outcomes such as sentinel 
node status or recurrence, and results are inconsistent (→study I). 
Further, the impact of a more detailed anatomic site division than the ICD code on patient 
survival is not clear, given the small size of most of these studies, and differences in inclusion 
and adjustment for confounders (see section 4.5) (→studies I and III). 
The impact of detailed anatomic site classified by intermittent and chronic UVR exposure 
has to our knowledge not been previously studied with regard to patient survival (→study 
III). 
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3 AIMS AND HYPOTHESES 
Overall aim 
The overall aim of this thesis was to investigate the role of detailed anatomic tumor site a in 
relation to sentinel node location, ultraviolet radiation (UVR) exposure patterns, genetic 
factors and prognosis of cutaneous melanoma. 
Specific hypotheses 
Specifically, we wanted to test the following hypotheses: 
1. The lower survival among patients with trunk melanoma (compared to extremity 
melanoma) is associated with uncommon and/or multiple sentinel node locations. 
2. Intermittent UVR exposure patterns, assigned by detailed tumor site, drive the incidence 
increase of cutaneous melanoma compared to chronic UVR exposure patterns. 
3a. Site-assigned intermittent UVR exposure is a negative prognostic factor compared to 
chronic UVR exposure. 
3b. Visibility upon skin self-examination is related to site-assigned UVR exposure and 
prognosis. 
3c. Subdivision of tumor site beyond the four major sites (head-neck, trunk, arms and legs) 
commonly used in survival analyses improves the accuracy of prognostic prediction. 
4. Site-assigned intermittent and chronic UVR exposure is associated with BRAF and 
NRAS genetic mutations, respectively. 
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4 METHODOLOGICAL CONSIDERATIONS 
4.1 SETTING 
The healthcare system in Sweden is publicly funded and every citizen is entitled to equal care 
within this system. It is organized into six regions, of which the Stockholm-Gotland 
healthcare region with about 2.3 million inhabitants (23% of the total population) (117) is the 
largest one with regard to population size, and the study base for studies II-IV. For study I, 
the Stockholm-Gotland healthcare region is part of the study base, together with the Western 
(1.9 million inhabitants) and Southern (1.8 million inhabitants) healthcare regions. 
4.2 STUDY DESIGN AND POPULATION 
The study design is a key element that defines a study’s ability to answer research questions. 
All studies in this thesis are retrospective cohort studies making use of prospectively 
collected register data. A retrospective cohort study is an observational study, i.e. the 
exposure of interest is not randomized or controlled, but merely observed, by the researchers 
of the study. This type of study can determine whether two factors (A and B) are associated 
to one another, but not whether factor A causes factor B. The cohort design means that 
individuals that differ regarding an exposure are followed over time and compared in relation 
to one or several outcomes.  
The population sample that is studied is called the study population. A population-based 
study means that the study sample is representative of the source population in the sense that 
all individuals of the source population that fulfill certain criteria are included. 
Study-specific aspects 
Study I is a population-based multicenter cohort. We included individuals diagnosed with 
primary invasive localized trunk or extremity melanoma who had undergone 
lymphoscintigraphy in three (Stockholm-Gotland, Western and Southern) healthcare regions 
from January 2000 to December 2006 (Sahlgrenska University Hospital) or 2008 (Karolinska 
University Hospital Solna, Södersjukhuset, Skåne University Hospital Lund). The individuals 
were identified from hospital registers. Since the procedure was introduced in Sweden during 
this period, eligibility criteria for the procedure were not static, but in brief consisted of 
invasive melanoma with a thickness of >1−1.5 mm, or <1 mm if other adverse characteristics 
were present. Individuals with traceable records in the Swedish Melanoma Register (SMR) 
and medical records that had undergone lymphoscintigraphy for a single invasive melanoma 
within six months of diagnosis (n = 859) remained in the study, whereas others (n = 69) were 
excluded. 
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Study II is a population-based cohort study from the Stockholm-Gotland healthcare region. 
The inclusion was register-based, with five bi-annual cohorts (1977−1978, 1983−1984, 
1989−1990, 1995−1996 and 2000−2001) of individuals diagnosed with invasive or in situ 
melanoma from the Regional Melanoma Register (RMR) (118) assessed for eligibility. To 
enable evaluation of detailed site of the primary tumor, we excluded individuals for whom the 
site of the primary tumor was unknown at diagnosis (n = 95). If an individual was diagnosed 
with more than one melanoma during the study period, the first was kept in the study whereas 
subsequent tumors were excluded. The final cohort consisted of 3,058 individuals. 
Study III is the third population-based study of the thesis and included all individuals 
diagnosed with invasive melanoma from 1976 to 2003 registered in the RMR. We excluded 
individuals with metastatic disease at diagnosis, more than one invasive melanoma, or 
missing data on detailed anatomic site of the primary tumor or the variables above (see 
original paper for details). In case of multiple tumors of which only one invasive lesion, the 
patient and the invasive lesion was kept in the study, whereas the in situ lesions were 
excluded. After exclusions, there were 5,973 individuals left to analyze. 
Study IV consists of one new and one previously studied cohort of individuals diagnosed 
with melanoma. The new cohort included 148 individuals with primary tumors located on the 
face or ears, diagnosed from 1996 to 2009 with representative samples available at the 
Department of Pathology at the Karolinska University Hospital Solna and a record in the 
RMR. 
The previously studied cohort included primary and/or metastatic melanomas with known 
mutation status for NRAS and BRAF, analyzed at the same department. The primary site of 
these melanomas was mostly trunk or extremities, and the year of diagnosis ranged from 
1977 to 2002. From this cohort, we excluded previously performed mutation analyses based 
on metastatic tissue only in the presence of multiple primary tumors or a primary tumor of 
unknown site (i.e. no reliable connection could be made to a single primary tumor site), and 
those without a primary tumor record in the RMR, leaving 183 individuals with 185 
melanomas for analysis. If both primary and metastatic tissue had been analyzed, we used the 
results of the primary tissue analyses. Together, the new and previously studied cohort 
included 331 individuals with 333 melanomas. 
4.3 EXPOSURES 
Exposure is a term used in epidemiology to define a factor that may (or may not) be 
associated with one or several outcome(s). 
In all studies (I-IV), the main exposure was detailed anatomic body site of primary 
cutaneous melanoma.  
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4.3.1 Quadrant model 
In study I, we first classified the 
body surface into two major 
anatomic areas: trunk and 
extremities. To enable more 
detailed analysis, we then divided 
the trunk further into 8 subsites: 
right (no. 1) and left (no. 2) upper 
anterior, right (no. 3) and left (no. 
4) lower anterior, right (no. 5) and 
left (no. 6) upper posterior, and 
right (no. 7) and left (no. 8) lower posterior quadrant. The extremities were divided into right 
(no. 9) and left (no. 10) upper, and right (no. 11) and left (no. 12) lower extremity. 
4.3.2 UVR exposure model 
Studies II-IV are based on a 
UVR classification model 
developed by Augustsson et al 
(119), that first appeared in 
scientific papers in the early 
1990s. The Augustsson model 
was designed to classify the 
body surface according to 
presumed clothing and sun 
exposure habits. The full 
model consists of 4 major anatomic sites, divided into 16 subsites: intermittent (no. 1−8), 
chronic (no. 9−10), rare (no. 11−13) and other (no. 14−16). The subareas are chest (no. 1), 
back (no. 2), anterior (no. 3) and posterior (no. 4) thighs, lateral arms (no. 5), anterior (no. 6) 
and posterior (no. 7) lower legs, dorsum of feet (no. 8), face (no. 9), dorsum of hands (no. 
10), medial arms (no. 11), lower abdomen (no. 12), buttocks (no. 13), scalp (no. 14), palms 
(no. 15), and soles (no. 16). 
In studies II−III, we modified the Augustsson model slightly and divided the intermittent 
area further into highly intermittent (no. 1−4) and moderately intermittent (no. 5−8) sites 
(paper IV), or intermittent (core) and intermittent (peripheral) sites as they were formerly 
referred to (paper III). The reason for this was an empirical observation/hypothesis that the 
central (core) parts of the intermittent category (chest, back and thighs) are exposed to the sun 
mainly during active sun bathing or summer sport activities, whereas the peripheral parts 
(lateral arms, lower legs and dorsum of feet) display a more continuous seasonal exposure. 
The relative body surface areas of the original two-dimensional model by Augustsson et al 
were estimated using a slightly adapted Lund & Browder method (120). The body surface 
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areas of the three-dimensional model created in SkinTrac© (see section 4.6) were similarly 
calculated by the computer software in relation to the whole-body surface. 
4.3.3 Skin visibility model 
In study III, we also classified 
the body surface according to 
presumed visibility upon skin 
self-examination, and major 
anatomic sites and subsites. In 
the empirical visibility 
classification, skin sites were 
divided into easily or poorly 
visible sites. Easily visible 
sites include the face, anterior 
ears, chest, abdomen, anterior upper arms and thighs, lower arms and legs, dorsum of hands 
and feet, and palms (no. 1), whereas poorly visible sites consist of the scalp, retroauricular 
area, posterior upper arms and thighs, buttocks, pubic area and soles (no. 2). 
4.3.4 Anatomic subsite model 
For the classification of 
anatomic subsites, we used a 
classification by Gillgren et al 
(116) from a previous article 
by our group. However, in this 
study we performed minor 
adjustments where the number 
of subsites were reduced to 23. 
We also merged the subareas 
into five major anatomic sites; 
trunk (no. 1−7), arms (no. 8−11), legs (no. 12−18), head-neck (no. 19−21) and acral (no. 
22−23). Subareas include the dorsal shoulders, superior back and clavicular area (no. 1), 
scapular and subscapular area (no. 2), middle and lower back (no. 3), supramammary and 
mammary area (no. 4), superior and middle abdominal area (no. 5), inferior abdominal area 
(no. 6), buttocks, pubic, genital and inguinal area and lateral hips (no. 7), upper (no. 8), 
middle (no. 9) and distal (no. 10) arms, dorsum of hands (no. 11), upper (no. 12), middle (no. 
13) and distal (no. 14) thighs, medial and lateral thighs (no. 15), knee and popliteal area (no. 
16), calves and achilleas area (no. 17), anterior lower legs and dorsum of feet (no. 18), face 
and ears (no. 19), scalp (no. 20), neck (no. 21), palms and soles (no. 22), and combined 
subungual area (no. 23). 
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4.4 OUTCOMES 
Outcome is a term used to define a factor that may (or may not) be linked with one or several 
causal factor(s), i.e. exposure(s). 
Patient survival 
In studies I and III, the main outcome was patient survival, defined as time from melanoma 
diagnosis to death. The main survival outcome measure was melanoma-specific survival, 
complemented by calculations of all-cause survival. Melanoma-specific death was 
determined by the main underlying cause of death in the cause of death certificate. In study I, 
the study endpoint was December 31st, 2011, and in study II December 31st, 2013. 
Individuals who were alive at the study endpoint, emigrated or died from other causes than 
melanoma during the follow-up period were censored in the main analyses. The term 
censored means that these individuals had not experienced the event of interest (in this case 
death) when last followed (the date of censoring), but information thereafter is missing. The 
time from diagnosis to the date of censoring is included in calculations as time at risk for the 
event of interest.  
Sentinel node locations 
In study I, we also evaluated the presence of uncommon, multiple, contralateral and 
inaccessible sentinel node locations. Uncommon sentinel node locations were defined as all 
non-regional (i.e. non-axillary, non-groin) locations, and classified by anatomic structures 
into epitrochlear, cervical, supra- or infraclavicular, intrathoracal or -abdominal, popliteal or 
interval/in-transit (i.e. located along the lymphatic system between the primary tumor and a 
lymph node basin) nodes. An individual with at least one uncommon node was classified into 
this category. Patients with more than one node location were defined as having multiple 
node locations, and those with at least one node on the opposite side of the body in relation to 
the primary tumor as having contralateral node location. Inaccessible nodes were defined as 
nodes that were not accessible for surgery according to the surgeon, or predetermined as 
accessible but not found upon surgery. Patients who had undergone lymphoscintigraphy with 
inconclusive results were also included in this category. Like above, individuals with at least 
one inaccessible node were classified into this category. 
Time trends 
In study II, the main outcome was time trends of overall melanoma incidence. As a 
secondary outcome, we evaluated incidence per body surface area (BSA). The time periods 
investigated were 1977−1978, 1983−1984, 1989−1990, 1995−1996 and 2000−2001. 
Individual-level data was obtained for individuals diagnosed with melanoma, whereas for the 
underlying (Stockholm-Gotland) population, aggregated end of year estimates were obtained 
by calendar year, 1-year age groups and sex. 
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Mutation status 
In study IV, the main outcome was NRAS (Neuroblastoma RAS viral (v-ras) oncogene 
homolog) and BRAF (V-raf murine sarcoma oncogene homolog B1) mutation status. For 
both genes, mutation status was defined as either mutated or wild type. For mutated samples, 
the specific mutated genotype was recorded. 
4.5 CONFOUNDERS AND INTERACTION VARIABLES 
The classic explanation of a confounder [A] is a factor that is independently related to (but 
not an intermediate of) a studied exposure and outcome and, as a result, may create false 
associations (type I error) or eliminate true associations (type II error) between the exposure 
and outcome. In studies of cause-specific associations, it is therefore vital to adjust for 
established as well as potential confounders. 
[A] 
𝐶 =  confounder 
𝐸 = exposure 
𝑂 = outcome 
 
In melanoma studies, confounders can be divided into patient- and tumor-related factors. Sex 
and age are regarded as classical confounding patient factors in most epidemiological 
studies, whereas tumor thickness according to Breslow, the presence or absence of ulceration, 
invasion level according to Clark, and histological type are common disease-specific 
confounding factors. 
During recent years, the use of directed acyclic graphs (DAGs) has become an increasingly 
popular alternative method to evaluate confounders in a complex setting. In a DAG, 
exposure, outcome and one or several other variables are connected by one-directed nodes 
and edges that do not form cycles. These factors can then be evaluated in a systematic fashion 
to determine the need of adjustment(s). DAGs were used together with conventional 
evaluation of confounders for all studies (I-IV) of this thesis. 
In studies I and III, data on sex, age, tumor thickness according to Breslow, the presence or 
absence of ulceration, and invasion level according to Clark were collected as potential 
confounders of the investigated association between tumor site and patient survival. Sex and 
age only were considered as confounders of the association between tumor site and sentinel 
node location (study I), and between tumor site and incidence trends (study II). 
Interaction occurs when the joint effect of two variables is greater than the individual effects 
put together. The net effect can be synergistic, antagonistic, additive or multiplicative. In 
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study I, we evaluated possible multiplicative interactions between sex, age and calendar 
period, and in study III between detailed anatomic site and visibility of skin site. 
4.6 DATA SOURCES 
Medical records 
The foundation of all studies (I−IV) was a medical record review for detailed body site of the 
primary tumor. For study I, the review also included information on sentinel node location 
and status. 
SkinTrac© 
Site was registered and body division models created in the software SkinTrac© (previously 
EssDoll©), a three-dimensional anatomic model of the human body developed for detailed 
site classification of the body surface by our group in the late 1990s (studies I−IV) (121). 
The precision of recorded tumors was classified on a five-level scale [0−2.5 cm, 2.5−5 cm, 5-
10 cm, 10-15 cm, or > 15 cm (previously “estimate”)] according to the maximum radius of 
uncertainty. The two best precision categories were equivalent to site information obtained 
from photographies, sketches or detailed text descriptions such as “5 cm above the left 
areola” or “right zygomatic bone”, whereas the third and fourth categories represented less 
precise descriptions such as “left popliteal fossa” and “right pectoral muscle”, respectively. 
The least precise category was used for descriptions such as “upper back”. If site information 
was available only from the ICD code (and not covered by the five-level scale), detailed body 
site was classified as missing in the present thesis. The latter differs slightly from the work by 
Gillgren et al (116), where such tumors were registered on the most common site among 
tumors registered within the three best precision categories for the anatomic area covered by 
the relevant ICD code. 
Registers 
The population-based Regional Melanoma Register of Stockholm and Gotland (RMR) 
(118) holds records of patients diagnosed with melanoma since 1976, and is the source of 
inclusion for studies II−IV. Data is prospectively reported by physicians in accordance with a 
care program (“Vårdprogram”), and includes various clinical and histopathological 
parameters such as date of diagnosis, ICD code and established confounders. For studies 
II−IV, all patient and tumor variables except detailed body site of the primary tumor were 
derived from the RMR. The coverage of the register is high, with a mean coverage of more 
than 98% for studies II and III.  
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The Swedish Melanoma Register (SMR) (122) was founded in 2003 to unite data from the 
regional melanoma registers, and the included variables are thus largely the same as for the 
RMR. The register was used in study I for inclusion, patient and tumor variables similarly to 
studies II−IV. 
The Cause-of-Death Register (123) is a national register that collects causes of death for 
deceased Swedish residents. The register is held by the National Board of Health and Welfare 
and data, used in studies I and III, include both the underlying and contributing causes of 
death classified by ICD codes. 
The Total Population Register is a national register held by Statistics Sweden, and the 
source of the emigration data in studies I and III (124). Statistics Sweden also compiles a 
broad range of official national and regional population statistics such as the size of the 
population by calendar year, sex and age (study II) (125). 
Mutation analyses 
New analyses of NRAS and BRAF mutation status were determined by standard (NRAS) or 
nested (BRAF) polymerase chain reaction (PCR) [B] and pyrosequencing [C] (study IV) 
(126,127). Previously published included analyses had been performed using the same 
method, complemented by (65), or only analyzed by (128), standard or seminested PCR 
followed by single strand conformational polymorphism (SSCP) and nucleotide sequence 
analysis [D]. 
[B] PCR is a method to copy a DNA (deoxyribonucleic acid) segment, where a DNA 
template containing the segment of interest, together with complementary oligonucleotides 
(primers), a DNA polymerase enzyme and nucleotides under the influence of thermic cycles 
generate a chain reaction of exponential DNA replication. Nested PCR is a two-step (outer 
and inner PCR) method to optimize correct binding. In study IV, the regions around NRAS 
exon 2 codon 61 and BRAF exon 15 codon 600 underwent PCR for amplification. 
[C] Pyrosequencing was named by the pyrophosphate release when a complementary 
nucleotide is added to a base of a single strand DNA during DNA synthesis. Given that 
nucleotides are added one by one (A, T, C and G) sequentially and that the release of 
pyrophosphate (through ATP and enzyme mediated reactions) emits light that is proportional 
to the amount of nucleotide incorporation, the DNA sequence of the single strand DNA can 
be visually determined as peaks on a pyrogram. 
[D] The form (conformation) of a single strand DNA sequence changes (polymorphism) if a 
base changes. This phenomenon can be seen as changed electrophoretic mobility and is 
utilized by SSCP to detect mutations. Since SSCP only detects the presence or absence of 
mutations, mutated samples need to undergo subsequent nucleotide sequence analysis to 
determine the specific genotype. 
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4.7 STATISTICAL METHODS 
Statistical methods are applied to make inference about true population estimates from 
sample data. 
Nonparametric tests 
To test differences in the distribution of categorical variables, we used the Fisher’s exact test 
[E] for basic variables (studies I−IV), and the chi squared test [F] for main variables (study 
IV). To describe differences in the distribution of basic numerical variables, we used the 
Wilcoxon rank-sum test (Mann-Whitney U test) [G] (studies I−IV). 
[E] The Fisher’s exact test calculates the exact probability of observed counts using 
factorials: 
𝑝 =
(𝑎 + 𝑏)! ∗ (𝑐 + 𝑑)! ∗ (𝑎 + 𝑐)! ∗ (𝑏 + 𝑑)!
𝑛! ∗ 𝑎! ∗ 𝑏! ∗ 𝑐! ∗ 𝑑!
 
a, b, c, d = observed frequency in cells a, b, c and d, respectively 
n =  sum of frequencies a + b + c + d 
 
[F] The chi squared test is based on the (squared) difference between observed and expected 
counts: 
𝑋2 = ∑ ∑
(𝑂𝑖𝑗 − 𝐸𝑖𝑗)
2
𝐸𝑖𝑗
𝑛𝑗
𝑗=1
𝑛𝑖
𝑖=1
 
n𝑖 = number of cells in row i 
n𝑗  =  number of cells in column j 
𝑂𝑖𝑗 = observed frequency in cell ij 
𝐸𝑖𝑗 = expected frequency in cell ij 
 
[G] The Wilcoxon rank-sum test is based on the difference between median values and 
compares the sum of ranks. The formula for large samples is displayed below: 
𝑊∗ =
𝑊 − 𝑛𝑠(𝑛𝑠 + 𝑛𝐿 + 1)/2
√
𝑛𝑠𝑛𝐿(𝑛𝑠+𝑛𝐿+1)
12
 
W = sum of ranks for smaller sample 
𝑛𝑠 =  sample size of the group with the smaller sum of ranks 
𝑛𝑠 = sample size of the group with the larger sum of ranks 
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Regression models 
Regression models are used to investigate the association between one or several independent 
(explanatory) exposure variables and a dependent (response/outcome) variable and are 
reported using various measures of relative risk (RR). Univariate (crude) regression models 
investigate one independent variable in relation to a dependent variable and return the 
combined association of the independent variable and possible confounders, whereas 
multivariate regression models include several independent variables and return the 
confounder-adjusted direct association between an independent and dependent variable of 
interest. 
In study 1, we used logistic regression models [H] to determine the association between 
detailed tumor site and sentinel node locations, and Cox proportional hazards regression 
models [I] to determine the association between the variables above and patient survival. The 
proportional hazards assumption was visually examined using a scatter plot of scaled 
Schoenfeld residuals over time. Cox proportional hazards regression was also used in the 
survival analyses of study III. In study III, the main analyses were complemented by 
competing risk regression models [J] to provide estimates in the presence of competing 
causes of death. In study II, we used Poisson regression models [K] to evaluate incidence 
trends of melanoma. 
[H] Odds is a risk measure of the probability (Pr) of experiencing an event versus the 
probability of not experiencing that event: 
𝑂𝑑𝑑𝑠 =
𝑃𝑟
1 − 𝑃𝑟
 
Odds ratio (OR) is used to compare the odds of two groups (exposed and unexposed): 
𝑂𝑅 =
𝑂𝑑𝑑𝑠𝑒𝑥𝑝𝑜𝑠𝑒𝑑
𝑂𝑑𝑑𝑠𝑢𝑛𝑒𝑥𝑝𝑜𝑠𝑒𝑑
 
Logistic regression is suitable when the dependent variable is dichotomous. It is estimated as 
an OR. The underlying odds function of exposed and unexposed is calculated as follows: 
𝐿𝑜𝑔(𝑜𝑑𝑑𝑠) = 𝛽0 + 𝛽1𝑥1 + 𝛽2𝑥2+ . . . +𝛽𝑛𝑥𝑛 
x =  independent variables 
β = coefficient for x 
 
[I] Cox proportional hazards regression estimates as a hazard ratio (HR), where the hazard 
represents the risk of experiencing an event of interest at a specific time, assuming survival 
up until that time: 
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𝐻(𝑡) = 𝐻0(𝑡) ∗ 𝑒𝑥𝑝(𝛽1𝑥1 + 𝛽2𝑥2+ . . . +𝛽𝑛𝑥𝑛) 
H(𝑡) = hazard at time t 
H0(𝑡)  =  hazard at time t when all variables x = 0 
x =  independent variables 
β = coefficient for x 
If the hazards in the nominator and denominator are proportional, the HR is constant over 
time: 
𝐻𝑅 =
𝐻𝑒𝑥𝑝𝑜𝑠𝑒𝑑(𝑡)
𝐻𝑢𝑛𝑒𝑥𝑝𝑜𝑠𝑒𝑑(𝑡)
= 𝑒𝑥𝑝(𝛽𝑒𝑥𝑝𝑜𝑠𝑒𝑑) 
 
[J] Competing risk regression according to Fine and Gray returns estimates for an event of 
interest (death due to melanoma), given that a competing event (death due to other causes) 
has not occurred. It is based on the subdistribution hazard function (in contrast to the cause-
specific hazard function of the Cox proportional hazards regression): 
𝐻∗(𝑡) = lim
∆𝑡→0
𝑃𝑟{𝑡 ≤ 𝑇 < 𝑡 + ∆𝑡, 𝜀 = 𝑘 | 𝑇 ≥ 𝑡 ∪ (𝑇 ≤ 𝑡 ∩ 𝜀 ≠ 𝑘)}
∆𝑡
 
𝐻∗(𝑡) = subdistribution hazard at time t 
𝑃𝑟 = probability 
𝑇 = event time 
𝜀 = event type 
𝑘 = event of interest 
 
[K] Incidence proportion (IP, also commonly referred to as cumulative incidence) is a risk 
measure of the proportion of new cases during a specific time period in a population: 
𝐼𝑃 =
𝑛𝑛𝑒𝑤 𝑐𝑎𝑠𝑒𝑠
𝑛𝑎𝑡 𝑟𝑖𝑠𝑘
 
To account for the rate with which new cases develop, incidence rate (IR), is preferred: 
𝐼𝑅 =
𝑛𝑛𝑒𝑤 𝑐𝑎𝑠𝑒𝑠
∑(𝑝𝑡𝑎𝑡 𝑟𝑖𝑠𝑘)
 
pt =  person­time 
Incidence rate ratio (IRR) is used to compare the IR of two groups (exposed and 
unexposed): 
𝐼𝑅𝑅 =
𝐼𝑅𝑒𝑥𝑝𝑜𝑠𝑒𝑑
𝐼𝑅𝑢𝑛𝑒𝑥𝑝𝑜𝑠𝑒𝑑
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Poisson regression can be modeled as a rate-based regression, where the log rate 
denominator (person-time) is handled as an offset. The regression estimate is a rate ratio 
(incidence rate ratio), where the underlying rate function (incidence rate) of exposed and 
unexposed is calculated as follows: 
𝐿𝑜𝑔(𝐼𝑅) = 𝛽0 + 𝛽1𝑥1 + 𝛽2𝑥2+ . . . +𝛽𝑛𝑥𝑛 
x =  independent variables 
β = coefficient for x 
 
Age-standardized incidence rates 
Age-standardized incidence rates by the direct method were used in study II to estimate 
incidence rates of melanoma over time in a (theoretical) setting where the age distribution of 
the underlying population is constant over time, thus removing the effect of age as a 
confounder. This is achieved by weighting the crude incidence rates to the age distribution of 
a standard population for whom the age distribution is known. We chose the Swedish 1979 
population as standard. The age-standardized incidence rate can be calculated as follows: 
𝐼𝑅𝑠𝑡 = ∑ 𝑑𝑖𝑤𝑖/𝑦𝑖
𝑖
 
IR𝑠𝑡 =  age­standardized incidence rate 
d𝑖 = number of cases in age group 𝑖 
w𝑖 = weight of age group i 
y𝑖 = person­time in age group i 
 
Tests of interaction 
In studies II and III, we performed tests of interaction using the multiplicative method [L], 
where interaction is indicated if, for the underlying RR function: 
[L] 𝛽1𝑥1 + 𝛽2𝑥2 +  𝛽12𝑥1𝑥2 ≠ 𝛽1𝑥1 + 𝛽2𝑥2 
β12x1𝑥2 =  interaction term 
 
Sensitivity analyses 
Sensitivity analyses are performed to test the robustness (sensitivity) of the obtained results to 
altered features of the primary analyses. In study III, sensitivity analyses were performed by 
using a broader definition of melanoma-specific death (including both underlying and 
contributing causes of death), and a stricter definition of UVR exposure site (excluding acral 
lentiginous melanoma). 
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5 RESULTS 
5.1 STUDY I 
Out of the 859 individuals with melanoma, 495 had melanoma located on the trunk and 394 
on the extremities. 66% of individuals with trunk melanoma were men, whereas those with 
extremity melanoma were mainly women (63%). 54% of trunk melanomas were located on 
the upper back. The presence of ulceration (37% vs 29%) or more than one positive sentinel 
node in the same sentinel node location (23% vs. 16%) was higher among trunk melanomas 
than extremity melanomas. 
Sentinel node location 
Multiple (31% vs. 7%) and contralateral (25% vs. 1%) sentinel node locations were more 
common among individuals with trunk melanoma, compared to extremity melanoma. 
Further, having multiple sentinel node locations correlated visually with a detailed anatomic 
site near the midline of the body (see original paper Suppl. figure 2). 
Uncommon sentinel node locations occurred with a similar frequency (8% vs. 7%) for 
individuals with trunk and extremity melanoma, including intrathoracal or -abdominal 
locations (3% vs 4%). Intraabdominal or -thoracal sentinel node locations among extremity 
melanomas were predominantly related to deep pelvic nodes originating from lower 
extremity melanomas (n = 13), whereas only one intrathoracal node location was observed 
among upper extremity melanomas. 
In multivariable sex- and age-adjusted models, trunk melanoma (compared to extremity 
melanoma) was strongly and independently associated with the presence of multiple 
(adjusted odds ratio (aOR) 7.1; 95% CI 4.6–11.5) and contralateral (aOR 32.2; 95% CI 15.1–
83.7) sentinel node locations, but not with uncommon sentinel node locations (aOR 1.1; 95% 
CI 0.6–1.9) (Table 5.1.1). 
Survival 
The median follow-up time was 4.9 years. During the study period, 147 individuals (21% of 
trunk melanomas; 12% of extremity melanomas) died from melanoma, and 45 (5% of trunk 
melanomas; 5% of extremity melanomas) from other causes. Three emigrated, whereas the 
rest were followed alive to the study endpoint. 
The adjusted hazard ratio (aHR) of melanoma-specific death was 1.9 (95% CI 1.3–2.9) for 
patients with trunk melanoma, compared to extremity melanoma. The risk was highest for 
individuals with tumors on the upper back (aHR 2.3, CI 1.4–3.6) and borderline higher (aHR 
2.0, CI 1.0–3.8) on the lower front, whereas those with tumors on the lower back and upper 
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front of the trunk showed no prognostic differences compared to the patients with melanoma 
on the extremities (Table 5.1.2). 
Patients with multiple, contralateral, uncommon or inaccessible sentinel node locations were 
not at increased risk of melanoma-specific death, compared to patients without these features 
(Table 5.1.3). It should be noted, though, that the number of events in the two last groups (i.e. 
uncommon and inaccessible) was low. 
 
Table 5.1.1. Adjusted odds ratios of multiple, contralateral or uncommon sentinel  
node locations by detailed body site of cutaneous melanoma. 
 Detailed site 
Sentinel node location 
Multiple  Contralateral  Uncommon 
aORa 95% CIb  aOR 95% CI  aOR 95% CI 
 Extremity 1.0 Refc  1.0 Ref  1.0 Ref 
 Trunk 7.1 4.6–11.5  32.2 15.1–83.7  1.1 0.6–1.9 
a  Adjusted odds ratio. Adjustments for sex and age. 
b  Confidence interval 
c  Reference category 
 
Table 5.1.2. Adjusted hazard ratios of melanoma-specific death by detailed body  
site of cutaneous melanoma. 
 Detailed site At risk (n) Events (%) aHRa 95% CI 
 Extremity 393 13 1.0 Ref 
 Upper back 251 24 2.3 1.4–3.6 
 Lower back 67 13 1.0 0.5–2.4 
 Upper front 79 19 1.6 0.9–3.0 
 Lower front 68 21 2.0 1.0–3.8 
a  Adjusted hazard ratio. Adjustments for sex, age, tumor thickness, ulceration, Clark invasion  
   level, sentinel node status, uncommon, multiple and contralateral sentinel node location. 
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Table 5.1.3. Adjusted hazard ratios of melanoma-specific death by sentinel node  
locations of cutaneous melanoma. 
 Sentinel node location At risk (n) Events (%) aHRa 95% CI 
 No   1.0 Ref 
 Multiple (yes) 171 19 1.1 0.4–2.9 
 Contralateral (yes) 118 25 1.0 0.4–2.5 
 Uncommon (yes) 66 11 0.5 0.2–1.4 
a  Adjustments for sex, age, tumor thickness, ulceration, invasion level, sentinel  
   node status, other sentinel node sites, and melanoma site. 
 
5.2 STUDY II 
The cohort consisted of 3,058 individuals diagnosed with melanoma during five time periods: 
1977−1978 (n = 321), 1983−1984 (n = 466), 1989−1990 (n = 730), 1995−1996 (n = 703) and 
2000−2001 (n = 838). Information on detailed anatomic site of the primary tumor was 
available in 93% of cases. Divided by ultraviolet radiation exposure (UVR) exposure site, 
1,653 had melanoma on highly intermittent† sites, 620 on moderately intermittent‡ sites, and 
391 on chronic sites. 
Individuals with melanoma on highly and moderately intermittent UVR exposure sites were 
on average younger (median age 56 / 59 years; interquartile range (IQR) 43−68 / 44−73) than 
those with melanoma on chronic UVR exposure sites (median age 71 years; IQR 59−79). 
Individuals with melanoma on highly intermittent UVR exposure sites were predominantly 
(60%) men, whereas those with melanoma on moderately intermittent UVR exposure sites 
were mostly (78%) women. Among individuals with melanoma on chronic UVR exposure 
sites, the difference in distribution between the sexes was smaller (45% men; 55% women). 
†  Referred to as intermittent (core) sites in the original manuscript. 
‡  Referred to as intermittent (peripheral) sites in the original manuscript. 
Age-standardized incidence rates 
Using the Swedish 1979 population as standard, the age-standardized incidence rate (IR) of 
melanoma increased on intermittent UVR exposure sites both among men (7.8 to 16.5 
cases/105 person-years) and women (7.6 to 14.6 cases/105 person-years) from the first time 
period to the last. The corresponding IR of melanoma on chronic UVR exposure sites 
increased from 1.7 to 2.3 cases/105 person-years among men, and from 1.4 to 1.8 cases/105 
person-years among women.  
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Poisson regression 
Adjusted for sex and age, the overall risk of melanoma on intermittent sites doubled over 
time (adjusted rate ratio (aRR) 2.1, 95% CI 1.8−2.4), with similar estimates for melanoma on 
highly intermittent (RR 2.1, 95% CI 1.8−2.5) and moderately intermittent (RR 2.1, 95% CI 
1.6−2.7) sites. Meanwhile, the adjusted relative risk of melanoma on chronic UVR exposure 
sites increased with 50% (aRR 1.4 (95% CI 1.0−1.9) (Tables 5.2.1−5.2.2). 
Sex and age 
The incidence increase of melanoma on intermittent UVR exposure sites was most 
pronounced in older age groups (> 65 years of age), especially among men (p < 0.0001). 
Meanwhile, the incidence increase on chronic UVR sites was stable (i.e. no significant 
interactions were detected) across different age groups and between the sexes. 
The relative risk of developing melanoma on highly intermittent UVR exposure sites was 
higher for men than for women (aRR 1.7, 95% CI 1.5−1.9), whereas the opposite was the 
case for moderately intermittent UVR exposure sites (aRR 0.3; 95% CI 0.3−0.4). For chronic 
UVR exposure sites, the risk of developing melanoma was only associated with advanced age 
(aRR 5.3, 95% CI 4.1−6.8 compared to the youngest age group). 
Invasivity 
Subgroup analyses revealed that invasive melanomas on intermittent UVR exposure sites 
increased over time (aRR 1.9, 95% CI 1.6−2.2) like the estimates of the overall data in this 
group, whereas those at chronic UVR exposure sites did not (aRR 1.0, 95% CI 0.7−1.4). In 
situ melanomas increased at both intermittent (adjusted RR 5.8, 95% CI 3.6−10.0) and 
chronic (adjusted RR 4.0, 95% CI 2.0−9.2) UVR exposure sites. 
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Table 5.2.1. Adjusted rate ratios of cutaneous melanoma at intermittent (overall) and  
chronic ultraviolet radiation (UVR) exposure sites by calendar period. 
 Calendar period 
UVR exposure site 
Intermittent (overall)  Chronic  
aRRa 95% CIb  aRR 95% CI  
 1977−1978 1.0 Refc  1.0 Ref  
 1983−1984 1.5 1.2–1.7  1.0 0.7–1.4  
 1989−1990 1.9 1.6–2.2  1.3 0.9–1.8  
 1995−1996 1.7 1.4–1.9  1.4 1.0–1.9  
 2000−2001 2.1 1.8–2.4  1.4 1.0–1.9  
a  Adjusted rate ratio. Adjustments for sex and age. 
b  Confidence interval 
c  Reference category 
 
Table 5.2.2. Adjusted rate ratios of cutaneous melanoma at highly intermittent  
and moderately intermittent ultraviolet radiation (UVR) exposure sites by calendar  
period. 
 Calendar period 
UVR exposure site 
Highly intermittent  Moderately intermittent  
aRRa 95% CI  aRR 95% CI  
 1977−1978 1.0 Ref  1.0 Ref  
 1983−1984 1.4 1.2–1.7  1.5 1.1–2.0  
 1989−1990 2.1 1.8–2.5  1.4 1.1–1.9  
 1995−1996 1.7 1.4–2.1  1.5 1.2–2.1  
 2000−2001 2.1 1.8–2.5  2.1 1.6–2.7  
a  Adjustments for sex and age 
 
5.3 STUDY III 
A total of 5,973 melanoma patients were analyzed. Of these, 52% were women and 48% 
were men. The distribution of melanoma sites differed between the sexes. Among men, 61% 
were trunk melanomas, whereas among women, trunk melanomas were the second most 
common category (33%), preceded by leg melanomas (39%). The site of the primary 
melanoma also differed by age of diagnosis, with a median age of 70 years among individuals 
diagnosed with head-neck melanoma, and 55 years among those with melanoma on the legs. 
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The median follow-up was 14 years. Of the 2,919 individuals who did not survive the entire 
follow-up period, 906 (31%) died from melanoma and the rest from other causes. 125 
patients were lost to follow-up due to emigration. 
UVR exposure model 
Classified by UVR exposure site, melanomas on highly intermittent UVR exposure sites were 
more common (60%) than those on moderately intermittent (23%) or chronic (13%) UVR 
exposure sites. Further, melanomas on highly intermittent UVR exposure sites displayed 
more favorable tumor characteristics (thickness, ulceration and invasion level), but a higher 
proportion of melanoma-specific death (16%) than those on moderately intermittent (13%) 
and chronic (12%) UVR exposure sites. 
With regard to patient characteristics, individuals with melanoma on highly intermittent UVR 
exposure sites were dominated by men (58%) and melanoma on moderately intermittent sites 
by women (76%), whereas those with melanoma on chronic UVR exposure sites displayed a 
more even sex distribution (women 52%, men 48%). The age at diagnosis was lower among 
individuals with highly intermittent (median 55 years) than moderately (59 years) or chronic 
(72 years) UVR exposure sites. 
The adjusted hazard ratio (aHR) of melanoma-specific death was lower among individuals 
with melanoma on moderately intermittent (aHR 0.7; CI 0.6−0.8) and chronic (aHR 0.6; CI 
0.4−0.7) UVR exposure sites than among those with melanoma on highly intermittent UVR 
exposure sites (Table 5.3.1). Sensitivity analyses using a broader definition of melanoma-
specific death (underlying or contributing cause of death) provided similar results for 
intermittent and chronic UVR exposure sites. Stratified analyses by sex also revealed similar 
associations. UVR exposure site was not associated with overall survival, which is not 
surprising given the long follow-up and large proportion of other-cause deaths (69% of all 
deaths). 
Skin visibility model 
Poor visibility of the primary melanoma site upon skin self-examination was associated with 
a higher relative risk of melanoma-specific death than easily visible sites even after 
multivariable adjustment for established confounders (aHR 1.3; CI 1.1−1.5) (Table 5.3.2). 
There was no significant interaction between the UVR exposure and skin visibility models. 
Anatomic subsite model 
Individuals with trunk melanoma were at increased risk of melanoma-specific death 
compared to those with melanoma on the arms, legs, head-neck, and acral sites (Table 5.3.3). 
Subdivision of the trunk, arms and legs did not improve prognostic prediction.   
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Among head-neck and acral sites, the neck, and palms and soles were associated with a 
higher relative risk of melanoma-specific death than the face and ears, and subungual sites, 
respectively (Table 5.3.4). However, the event numbers in these categories were rather small. 
 
Table 5.3.1. Adjusted hazard ratios of melanoma-specific death by ultraviolet radiation  
(UVR) exposure site. 
 UVR exposure site 
At risk  Events  Partial model  Full model  
n  %  apHRa 95% CIb  afHRc 95% CI  
 Highly intermittent 3,600  16  1.0 Refd  1.0 Ref  
 Moderately intermittent 1,371  13  0.9 0.7–1.0  0.7 0.6–0.8  
 Chronic 609  12  0.7 0.5–0.9  0.6 0.4–0.7  
a  Partially adjusted hazard ratio. Adjustments for sex, age and year of diagnosis. 
b  Fully adjusted hazard ratio. Adjustments for sex, age, year of diagnosis, tumor thickness, ulceration,  
   and Clark invasion level. 
c  Confidence interval 
d  Reference category 
 
Table 5.3.2. Adjusted hazard ratios of melanoma-specific death by skin visibility upon  
skin self-examination. 
 UVR exposure site 
At risk  Events  Partial model  Full model  
n  %  apHR 95% CI  afHR 95% CI  
 Easily visible 3,311  13  1.0 Ref  1.0 Ref  
 Poorly visible 2,662  18  1.3 1.2–1.5  1.3 1.1–1.5  
 
Table 5.3.3. Adjusted hazard ratios of melanoma-specific death by major anatomic site. 
 Major anatomic sites 
At risk  Events  Partial model  Full model  
n  %  apHR 95% CI  afHR 95% CI  
 Trunk 2,887  18  1.0 Ref  1.0 Ref  
 Arms 800  11  0.6 0.5–0.7  0.5 0.4–0.6  
 Legs 1,497  12  0.7 0.6–0.9  0.6 0.5–0.7  
 Head-neck 686  14  0.7 0.6–0.9  0.6 0.5–0.8  
 Acral 103  27  1.5 1.0–2.1  0.6 0.4–1.0  
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Table 5.3.4. Adjusted hazard ratios of melanoma-specific death by anatomic subsite. 
 Anatomic subsites 
At risk  Events  Partial model  Full model  
n  %  apHR 95% CI  afHR 95% CI  
 Head-neck           
    Face and ears 549  12  1.0 Refd  1.0 Ref  
    Scalp 44  27  2.6 1.4–4.8  1.2 0.7–2.3  
    Neck 93  19  1.7 1.0–2.8  1.8 1.0–3.0  
 Acral           
    Palms and soles 68  29  1.0 Ref  1.0 Ref  
    Combined subungual 
    area 
35  23  0.7 0.3–1.5  0.2 0.2–1.0  
 
5.4 STUDY IV 
Of the eligible new samples, DNA extraction/PCR was successful for 139 samples (94%). Of 
these, NRAS mutation status was determined for all samples, and BRAF mutation status for 
91%. Adding the 185 previously studied samples, the final cohort consisted of 324 samples. 
145 samples originated from melanomas on chronic UVR exposure sites, and 164 from 
melanomas on intermittent UVR exposure sites. Individuals with melanoma on chronic UVR 
exposure sites were older than those with melanoma on intermittent UVR exposure sites 
(median 75 vs. 62 years). Further, melanomas on chronic UVR exposure sites were thinner 
(median 1.6 vs. 2.6 mm), less invasive (33% vs. 1% in situ) and less ulcerated (19% vs. 45%) 
than those on intermittent UVR exposure sites. The most common histological type was 
lentigo maligna melanoma (LMM, 47%) on chronic UVR exposure sites, and superficial 
spreading melanoma (SSM, 50%) on intermittent UVR exposure sites. 
Mutation status 
The overall proportion of BRAF and NRAS mutated tumors was lower on chronic UVR 
exposure sites than on intermittent UVR exposure sites. BRAF mutations were more common 
than NRAS mutations in samples originating from melanomas on intermittent UVR exposure 
sites (49% vs. 28%), whereas NRAS mutations were more common than BRAF mutations 
(17% vs. 10%) in samples originating from melanomas on chronic UVR exposure sites. The 
mutations were mutually exclusive except for one sample. Using the Χ
2 test, BRAF mutations 
were associated with intermittent UVR exposure sites, and NRAS mutations with chronic 
UVR exposure sites (p-value < 0.0001) (Table 5.4.1). 
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Table 5.4.1. Χ2 test of mutation statusa by UVR exposure site. 
 Mutation status 
UVR exposure site 
Intermittent Chronic p-value 
 BRAF mutated 81 13 < 0.0001 
 NRAS mutated 46 22  
 Wild type 35 96  
a  Not including 15 tumors with undetermined BRAF status, and 1 with both BRAF and NRAS  
   mutations 
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6 DISCUSSION 
CAUSALITY 
All studies (I−IV) in this thesis measure associations and not causality. This implies that a 
statistical association between factor A and factor B does not (necessarily) mean that factor B 
is caused by factor A; it simply implies that the two factors relate to each other. Causality on 
the other hand measures whether factor B is, or is not, an effect of factor A. These differences 
need to be kept in mind when interpreting the results. The evidence obtained from well-
performed cohort studies is preceded only by controlled trials. 
6.1 INTERNAL VALIDITY 
Internal validity can be explained as the ability of a study to measure what it intended to 
measure, i.e. (causal) associations. This ability is crucial to all scientific studies, and a high 
internal validity is characterized by a lack of bias as well as unadjusted confounding. It is 
also of interest to have a low probability of chance findings. 
6.1.1 Bias 
Bias is a systematic error in the design of a study that may create spurious associations 
between the exposure and outcome(s) of interest, either removing true associations or 
evoking (positive or negative) associations that are in reality not there. The feature that makes 
bias especially problematic compared to confounding is that its effect cannot be removed or 
adjusted for in statistical analyses. Neither can it be reduced by increasing the study sample. 
Hence, avoiding or minimizing bias is a main concern already at the design phase in all 
studies. 
The nomenclature to describe different types of bias is extensive and not very consistent. 
However, bias can be roughly divided into two categories, selection bias and information 
bias, based on underlying mechanisms. 
Selection bias occurs when the individuals in the study sample differ from the source 
population with regard to the risk of being exposed or developing the outcome of interest. 
Information bias (also commonly referred to as observation bias) instead refers to 
misclassification or measurement error. Information bias can be dependent (differential) or 
independent (non-differential) of the exposure of interest, and affect exposure as well as 
outcome(s) and confounders.  
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Study-specific aspects 
The population-based design of studies I−III reduces the risk of selection bias in these 
studies, whereas the tissue samples analyzed in study IV may be at greater risk of this type of 
bias. 
As for information bias, there is a possibility of misclassification of exposure, i.e. detailed 
anatomic site of the primary cutaneous melanoma in all studies (I−IV) due to the 
retrospective review of medical records and uncertainty of recordings. Further, the 
determination of UVR exposure pattern is based on presumed exposure by body site and not 
on actual exposure data such as individual sun habits and protective measures. Neither can we 
rule out the possibility of misclassification of outcome(s), represented by sentinel node 
location and status (study I), causes of death (studies I and III) and mutation status (study 
IV). Established confounders are less likely to be misclassified, given the prospective 
registration and high validity of these patient and tumor characteristics in the regional and 
national quality registers. 
To reduce the risk of misclassification of detailed anatomic site (studies I−IV), we put large 
efforts into the data collection. This is reflected in the low uncertainty (an estimated radius of 
<5 cm) in the majority of site recordings. 
The main concern with regard to the laboratory analyses in study IV was the possibility of 
measurement error, i.e. the possibility of false classification of tissue samples as wild type in 
the presence of mutations. To reduce this risk, we applied established laboratory methods (see 
section 4.6). However, it should be kept in mind that the sensitivity of these methods is not 
100% and a differentially misclassified component cannot be excluded. 
The accuracy of the reported causes of death in the Cause-of-Death Register is strengthened 
by the fact that death certificates are provided by the treating physicians, but may be 
inaccurately captured in some cases. Also, the distinction between underlying and 
contributing causes of death may be equivocal. In the main analyses of this thesis, we 
classified death as melanoma-specific only when melanoma was registered as the underlying 
cause of death, thereby increasing the positive predictive value of the classification (studies I 
and III). We also re-computed all analyses using all-cause death as outcome. 
The fact that the estimates in study I changed only marginally during the five-year median 
follow-up in analyses of overall compared to melanoma-specific death indicates that most 
deaths within this time period were melanoma-specific, and that a potential degree of false-
negative misclassification of melanoma-specific deaths would hardly have influenced the 
results at all. Meanwhile, the lack of differences in overall survival in study III is not 
surprising given the long median follow-up (14 years), entailing a large number of other-
cause deaths among both exposed and unexposed that dominated these analyses. 
In study III, we also added a sensitivity analysis where we changed the definition of 
melanoma-specific death to include both underlying and contributing causes of death listing 
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melanoma. The reason for this was that individuals diagnosed with melanoma on chronic 
UVR exposure sites were on average older and thus at a higher risk of dying from other 
causes than melanoma, which may reduce the likelihood of melanoma being accurately 
classified as the underlying cause of death. 
6.1.2 Confounding 
Confounding (see section 4.5) is the second major threat to the internal validity of a study. 
However, confounders may be controlled for in analyses through statistical adjustment, 
stratification or restriction of the confounding variable, hence removing the effect of this 
variable from the (causal) association under investigation. 
In this thesis, we used multivariable regression analysis to enable simultaneous adjustment of 
potential and established confounders (studies I and III). However, there are still several 
pitfalls related to adjustment. First, confounding variables must be carefully assessed and 
only true confounders included to avoid overadjustment (129). Second, all true confounders 
need to be included and properly quantified to avoid residual confounding. 
Study-specific aspects 
To avoid overadjustment and minimize the risk of residual confounding, we pre-assessed the 
exposure(s), outcome(s) and established as well as potential confounders using directed 
acyclic graphs (DAGs) (see section 4.5) for all studies (I−IV). Further, we modeled 
continuous variables linearly (studies I and III) or using splines (for non-linear variables) 
(study III) instead of categorization when applicable. 
The fact that sex, age and established tumor factors such as thickness, the presence or absence 
of ulceration and Clark invasion level are prospectively recorded in the RMR and SMR 
facilitated proper adjustment for these factors. However, there may be some residual 
confounding due to unidentified or unmeasured confounders. These include comorbidities, 
socioeconomic and cohabitation status with regard to patient survival (studies I and III) and 
sentinel node status (study III). For study I, information on sentinel node status was collected 
as part of the medical record review. 
6.1.3 Chance 
Lastly, there is the possibility of chance findings, often referred to as random error. The 
probability of chance findings is estimated using p-values and/or confidence intervals. 
Whereas p-values only assess the probability of finding an estimate of the same, or a more 
extreme, magnitude by chance only, confidence intervals quantify this uncertainty by 
providing an interval that with a pre-set probability contains the true population estimate, 
while also indirectly providing the information of a p-value. Hence, confidence intervals are 
more informative when evaluating statistical associations. 
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The p-value and confidence interval limits are constructed cut-off levels to determine whether 
associations are statistically significant. The significance (alfa) level is often set to 5% (0.05) 
for p-values, corresponding to a 95% confidence interval, but can be altered to achieve 
increased precision. 
The possibility of chance findings can never be eliminated, but the risk is reduced with 
increasing sample size and number of outcome events. 
Study-specific aspects 
In all studies (I−IV), the significance level was pre-set to 0.05. In studies I−III, the main 
estimates of association were reported together with confidence intervals (with or without p-
values), whereas p-values only were calculated for study IV. Further, the sample sizes were 
larger, and the risk of chance findings hence lower, than in most previous studies. 
6.2 EXTERNAL VALIDITY 
External validity refers to the extent to which the conclusions of a study are generalizable to 
populations other than the one studied. External validity is often high for large observational 
studies, especially population-based studies, since the study population and the source 
population are similar (given that the internal validity is also high). This is also the reason 
why well-performed high-internal validity RCTs may be at risk of low external validity; the 
selection of study participants may generate conclusions that are true only under a strict set of 
criteria. 
Study-specific aspects 
The generalizability of studies I−III is high due to the population-based design and an 
estimated high internal validity. In study IV, the latter is more difficult to determine. Further, 
this thesis only investigates cutaneous melanoma. Conclusions thus cannot be applied on 
non-cutaneous melanoma (mucosal melanoma, ocular melanoma). 
6.3 FINDINGS AND IMPLICATIONS 
6.3.1 Study I 
Sentinel node location 
We found that cutaneous melanoma located on the trunk was associated with multiple and 
contralateral but not uncommon sentinel node locations, compared to melanoma located on 
the extremities. 
The prevalence of multiple sentinel node locations in trunk melanoma was in the upper range 
of previous studies (106–112) and, as hypothesized, much higher than that of extremity sites. 
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However, the fact that we did not find any differences in the prevalence of uncommon 
sentinel node locations between trunk and extremity sites was against our a priori hypothesis, 
and influenced by an unexpectedly high frequency of deep pelvic nodes among extremity 
melanomas. The observed preponderance of multiple sentinel node locations near the midline 
of the body was an interesting side finding, although for anatomic reasons maybe not very 
surprising. 
Survival 
In the survival analyses, we confirmed that individuals with cutaneous melanoma located on 
the trunk had a reduced melanoma-specific survival compared to those with melanoma on the 
extremities. This was especially evident for melanoma subsites on the upper back. Multiple, 
contralateral or uncommon sentinel node locations were however not associated with 
survival.  
There are not many studies on detailed anatomic trunk site and patient survival and those that 
exist are not consistent (116,130–135). Hence, the fact that we found prognostic differences 
within the trunk area, and that the subsite of interest overlaps with the BANS (upper back, 
posterior arm, neck and scalp) (130) and TANS (thorax (back and breast), upper arm, neck 
and scalp) (136) areas was interesting. 
The lack of association between multiple sentinel node locations and patient survival is in 
line with two smaller (109,112) and one larger (110) previous study, but not with another 
smaller (108) study. In other words, evidence is still not clear but increasingly points toward 
multiple sentinel node locations as unrelated to prognosis. 
There are even fewer studies on uncommon sentinel node locations and patient survival 
(98,99), perhaps due to the rareness of these events. Further, the definition of uncommon 
sentinel node location differs between studies, complicating comparisons. Still, our results 
together with a larger study of interval nodes support the lack of association with survival for 
uncommon sentinel node locations, although inference in our study was somewhat limited 
due to low event numbers.  
It should also be noted that inaccessible nodes (see section 4.4) were more common among 
uncommon than common sentinel node locations, and that the evaluation of uncommon 
sentinel node locations and survival included adjustment for these nodes. Although 
inaccessible nodes were not associated with a reduced survival in our study, the HR and 
confidence interval tended toward the latter (aHR 1.9, 95% CI 0.8−4.2 compared to verified 
negative nodal status). It is feasible to hypothesize that this may reflect the presence of 
positive as well as negative nodes among these unexplored inaccessible nodes. The lack of 
surgical node exploration was in fact a major limitation of a smaller study (99) of patients 
with in-transit sentinel node locations that showed opposite results.  
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Strengths 
Strengths of the study include the population-based design, the detailed anatomic site 
description, and the use of prospectively collected quality register data and high-coverage 
national register data for confounders and causes of death/losses to follow-up (emigration), 
respectively. 
Limitations 
Limitations include limited power to detect smaller prognostic differences, potential 
misclassification of detailed anatomic site due to the retrospective study design, potential 
underestimation of (uncommon) SNLs in the lymphatic mapping procedure and/or 
documentation of the latter, and potential misclassification of causes of death (see section 
6.1.1). 
6.3.2 Study II 
Incidence increase 
We found that site-assigned intermittent UVR exposure was a driver of the incidence increase 
of cutaneous melanoma, whereas site-assigned chronic UVR exposure appeared to be of less 
importance. The incidence increase of melanoma on intermittent UVR exposure sites was 
influenced by age- and sex-specific factors, whereas that of chronic UVR exposure sites was 
not.  
Although causality is not applicable, these findings support the hypothesis of intermittent 
UVR exposure (15–25) as a main risk factor behind the incidence increase of cutaneous 
melanoma. The presence of sex-specific risk patterns and interactions between calendar 
period, age and sex on these sites may reflect influence from behavioral aspects (137) such as 
clothing, sun habits and protective measures, although biological factors (138,139) may also 
contribute to site differences between the sexes. Meanwhile, the absence of the features above 
but a clear association with advanced age implies that chronic UVR exposure is largely 
related to cumulative sun-induced damage, which may be less prone to changes over time. 
Analyses of invasive and in situ melanomas separately supported that a component of 
diagnostic drift (2) and/or improved early detection may have taken place during the study 
period. However, the overall conclusions were not affected by this. 
Another interesting observation, which was not in line with our a priori hypothesis, was that 
we could not detect any differences in relative incidence increase between highly intermittent 
and moderately intermittent sites. It is unclear to which degree the experimental nature of this 
categorization may have influenced these results. 
Possible biological mechanisms behind the stronger incidence increase detected among 
melanomas on intermittent than chronic UVR exposure sites include a preponderance of 
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sunburn (19–24,26–34) on these sites, whereas the development of a gradual tan from chronic 
UVR exposure has been suggested as protective factor against sunburn. 
Strengths 
Strengths include (like above) the population-based design, the detailed anatomic site 
description, and the use of quality register as well as high-coverage national register data. 
Limitations 
Limitations chiefly concern the lack of actual individual UVR exposure data. Other 
limitations include the lack of data for the past 15 years, during which age and sex-specific 
sun behavior as well as diagnostic criteria may have changed.  
Still, it may be argued that the use of site as a proxy variable for UVR exposure patterns is 
likely to be at lower risk of self-selection and recall bias, and a less subjective measure of 
exposure than that obtained from self-assessment in interview/questionnaire studies. Further, 
proper randomization of UVR exposure is difficult, and well-performed population-based 
large observational studies may often be the best level of evidence available.  
Given the difficulties involved in evaluating individual UVR exposure patterns over a 
lifetime, there is a need for different approaches to measure this exposure. Hence, the 
classification of presumed UVR exposure based on detailed anatomic site may, together with 
other studies of different limitations, contribute to important knowledge with regard to 
primary prevention. 
6.3.3 Study III 
UVR exposure model 
We found a lower melanoma-specific survival among individuals diagnosed with melanoma 
on highly intermittent UVR exposure sites than among those with melanoma on chronic or 
moderately intermittent UVR exposure sites, independently of differences in established 
patient and tumor factors or skin visibility upon self-examination (SSE). 
These results are interesting given that the few previous studies addressing this research 
question have shown no (140), or a borderline protective (141,142), association between 
intermittent UVR exposure and melanoma-specific survival. These previous questionnaire or 
interview studies were not (fully) adjusted for tumor factors, and all but one (140) were 
smaller than ours. Further, the definitions and measures of intermittent UVR exposure varied 
between the studies and some may not have fully captured the exposure. 
The results for chronic UVR exposure sites are in line with previous studies of markers of 
cumulative sun-induced damage and patient survival (141,143). 
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Whereas increased levels of vitamin D, nitric oxide (144), melanin and DNA damage-repair 
(141,145) have been suggested as plausible protective UVR-related mechanisms behind 
favorable outcomes, the underlying biology of a possible association between intermittent 
UVR exposure and an unfavorable outcome has been less elaborated. Since BRAF mutations 
have been separately linked to sunburn (41), primary location on the trunk (37,62–65), skin 
areas with no or low signs of cumulative sun-induced damage (37–40,62), and (variably to) 
reduced survival (146), it would be interesting to look further into BRAF mutations in this 
context. 
Skin visibility model 
The reduced survival we found among individuals with melanoma on poorly, compared to 
easily, visible skin sites upon SSE even after adjustments of established prognostic factors 
was an unexpected finding, as was the lack of significant interactions with UVR exposure 
site. Although differences in UVR patterns may partially explain the results, other biological 
mechanisms may be involved and increased attention to these sites is warranted. 
Anatomic subsite model 
Although we detected prognostic differences upon subdivision of head-neck and acral sites, 
these findings were limited by low event numbers. The most interesting finding from the 
anatomic subsite model, and against our a priori hypothesis, was instead the lack of 
statistically significant prognostic differences within the trunk and extremities. These results 
contrast with the findings from study I as well as those of a previous study from our group 
(116), although the studies are not directly comparable due to different categorizations and 
statistical approaches.  
The detailed categorization used may contribute to a limited power for individual subsites, 
and we cannot exclude the possibility that we might have been able to detect prognostic 
differences by combining subsites into larger areas or by increasing the sample size. For 
example, we noted that melanoma-specific death among individuals with trunk melanoma 
was more common for melanoma subsites on the thorax and back (subsites no. 1−4; 
17.1−19.8%) than on the abdomen and lower trunk (subsites no. 5−7; 13.4−14.5%). On the 
other hand, this is to our knowledge the largest study performed on detailed anatomic site and 
patient survival, and it may be sufficient to conclude that a detailed subdivision of the trunk 
and extremities does not appear to add any large prognostic value. 
Strengths 
As for studies I and II, strengths include the population-based design, the detailed anatomic 
site description, the use of quality register as well as high-coverage national register data. The 
study is also of appreciable size, especially considering that the assessment of exposure is 
based on medical record reviews. 
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Limitations 
Limitations are also largely shared by studies I and/or II, and include limited power to detect 
smaller prognostic differences, potential misclassification of detailed anatomic site due to the 
retrospective study design, inherent limitations from the lack of individual actual UVR 
exposure data and use of detailed site as a proxy variable of the latter, lack of adjustment for 
sentinel node status and potential other confounding from comorbidities, socioeconomic (83) 
and cohabitation (84) status, and potential misclassification of causes of death (see section 
6.1.1). 
6.3.4 Study IV 
We confirmed our hypothesis that BRAF mutations were associated with melanoma on 
intermittent UVR exposure sites, and NRAS mutations with melanoma on chronic UVR 
exposure sites. Further, we observed that the overall prevalence of BRAF and NRAS 
mutations among melanomas on chronic compared to intermittent UVR exposure sites was 
low. 
This has previously been implicated in studies where intermittent and chronic UVR exposure 
were defined by major anatomic sites and/or the absence or presence of signs of chronic sun-
induced damage (37–40,62–65) but is now demonstrated in a large cohort using an 
established UVR exposure model. Although causality cannot be determined, the results 
support that NRAS and BRAF mutations are related to different UVR exposure patterns, but 
also imply that other genetic mechanisms (40,147,148) may be more relevant with regard to 
chronic UVR exposure and melanoma development. 
An association between BRAF mutations and intermittent UVR exposure is biologically 
supported by a demonstrated increased incidence of melanoma among BRAF V600E mutated 
mice (compared to non-V600E BRAF mice) after UVR exposure resulting in sunburn (41). 
Strengths 
Strengths include the detailed anatomic site description, the use of quality register data and 
robust methods for mutation screening, and the large sample size. 
Limitations 
Although it has been demonstrated that NRAS and BRAF mutations are early events and that 
detected mutations in metastatic tissue can be extrapolated to the primary lesion, the use of 
primary tumor tissue samples in the new cohort vs. metastatic tissue in the majority of 
samples in the previously studied cohort may constitute a limitation of the study, as may the 
use of partially different screening methods [pyrosequencing (new) vs. pyrosequencing/SSCP 
and nucleotide sequence analysis (prev. studied)] and sample storage methods [formaline-
fixed paraffine-embedded (FFPE; new) vs. fresh frozen/FFPE (prev. studied)] between the 
new and previously studied cohort, and the long storage time for the majority of the samples. 
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7 CONCLUSIONS 
Summary conclusion 
 
Specific conclusions 
Study I 
• Trunk melanoma is related to multiple sentinel node locations, with a visual 
preponderance near the midline of the body. 
• Trunk melanoma is related to increased risk of melanoma-specific death, especially if 
located on the upper back. 
• Trunk melanoma is not related to uncommon sentinel node locations. 
• Multiple and uncommon sentinel node locations are not related to increased risk of 
melanoma-specific death. 
Study II 
• Melanoma located on intermittent UVR exposure sites increased more over time than 
melanoma on chronic UVR exposure sites. 
• The incidence increase of melanoma on intermittent UVR exposure sites was most 
pronounced in older age groups (> 65 years of age), especially among men. 
• The incidence increase on chronic UVR sites was stable across different age groups and 
between the sexes.  
The main conclusions of this thesis are that: 
• The lower survival among patients with trunk melanoma (compared to the extremities) 
is not related to uncommon or multiple sentinel node locations (study I). 
• Site-assigned intermittent UVR exposure appears more relevant than chronic UVR 
exposure for the incidence increase of cutaneous melanoma (study II). 
• Site-assigned intermittent UVR exposure is a negative prognostic factor compared to 
chronic UVR exposure (study III). 
• Site-assigned intermittent UVR exposure is related to BRAF mutations, and chronic 
UVR exposure to NRAS mutations (study IV). 
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Study III 
• Melanoma located on highly intermittent UVR exposure sites are related to a lower 
patient survival than moderately intermittent and chronic UVR exposure sites. 
• Melanoma on poorly visible sites upon skin self-examination are also related to a lower 
patient survival than easily visible sites. 
• Subdivision of the major anatomic sites trunk, arms and legs is not clinically relevant 
with regard to patient survival. 
Study IV 
• Intermittent UVR exposure sites are related to BRAF mutations, and chronic UVR 
exposure sites to NRAS mutations in melanoma. 
• BRAF and NRAS mutations are less prevalent on chronic UVR exposure sites than on 
intermittent UVR exposure sites. 
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8 FUTURE PERSPECTIVES 
In Australia, decades of systematic UVR protection approaches have resulted in a decline in 
the incidence of melanoma among adolescents and young adults (149). However, whereas the 
UV index in Australia is constantly high or very high, the Swedish UV index is 
predominantly low with only short periods of high levels, and successful strategies in 
Australia cannot be assumed to have similar impact in a high-latitude setting. 
Given the continued incidence increase of melanoma in Sweden, there is an imperative 
incentive to re-evaluate the primary prevention efforts of melanoma used so far. To achieve 
this, large-scale studies, such as nationwide pre-post intervention trials, and cluster 
randomization of kindergartens, child health centers and outdoor sport clubs, are needed.  
The interventions should be coordinated by a single institution or authority, with a multi-
professional team of physicians, epidemiologists, statisticians, economists, administrators, 
educators and public relations professionals, and collaborations with dermatological and 
oncological organizations. 
In addition to conventional information by authorities and healthcare, the public should be 
actively approached from multiple sources with a focus on social media, TV, radio and 
newspaper advertising. 
There should be multiple research questions/interventions. For example, it would be 
interesting to evaluate the impact of appearance-related interventions and the use of UV index 
and sun protection advice through mobile apps such as “Min soltid” by the Swedish 
Radiation Authority (150) among young people, and the impact of UV index guided sun 
protective measures (shadow, clothing, sunscreen) by kindergarten teachers and sport club 
leaders, and parent education by pediatric nurses. An important intervention by the Swedish, 
Finnish, Norwegian and Icelandic Radiation Authorities (151) to follow, is the prohibition 
against the use of solar beds for cosmetic purposes for children and adolescents that will take 
place in 2018. 
Short- as well as long-term outcomes should be evaluated. Short-term outcomes of interest 
include different measures of UV exposure as well as the prevalence of nevi and erythema 
(markers of intermittent UVR exposure and sunburn), whereas long-term outcomes include 
the incidence of melanoma. It would also be interesting to look at melanoma-specific, 
cardiovascular and overall survival in this context. Nationwide register-based outcomes 
should be combined with in-depth surveys on sample cohorts. 
This would naturally demand a sizeable long-term funding. However, it is important not to 
forget that the costs of primary prevention should be evaluated in relation to the costs related 
to melanoma on a societal level (6). Of these, there are not only direct costs related to 
healthcare, but also indirect costs from productivity losses. 
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The perspectives above are not novel; several measures are in fact already covered by the 
Swedish Radiation Authority (152). Many aspects were also discussed during the Vadstena 3 
meeting “Facts and consensus about skin cancer prevention” (Svenska 
Dermato‐Epidemiologiska Nätverket (SveDEN) and Svenska Sällskapet för Dermatologisk 
Kirurgi och Onkologi (SDKO), 2016). 
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9 SAMMANFATTNING PÅ SVENSKA 
Bakgrund: Samspelet mellan primär tumörlokalisation, exponering för ultraviolett (UV) 
strålning, genetiska faktorer, insjuknande i och överlevnad vid malignt melanom är komplext. 
I denna avhandling syftade vi att undersöka effekterna av detaljerad tumörlokalisation bortom 
den konventionella och strikt anatomiska uppdelningen i huvud-hals, bål, övre och nedre 
extremiteter, med fokus på indelning av kroppsytan enligt UV-exponeringsmönster i 
förhållande till dessa faktorer. 
Metoder: Vi inhämtade och registrerade detaljerad information avseende primärtumörens 
lokalisation i ett skräddarsytt datorprogram, och klassificerade (beroende på studie) 
kroppsytor enligt dominerande UV-exponeringsmönster, synlighet för ögat vid 
självundersökning av huden, samt anatomiska uppdelningar mer detaljerade än ICD-
klassifikationen (International Classification of Diseases) (studie I–IV). Genom länkning till 
regionala och/eller nationella register erhöll vi (beroende på studie) uppgifter om insjuknande 
och överlevnad såväl som etablerade störfaktorer och (i förekommande fall) bortfall. Vi 
inhämtade även information avseende lokalisation och status för portvaktskörtel/-körtlar 
(studie I), och utförde PCR och pyrosekvensning för detektion av mutationer i proto-
onkogenerna BRAF och NRAS (studie IV). 
Resultat: Melanom på bålen var associerat med förekomst av multipla men inte ovanliga 
sentinel node-lokalisationer jämfört med melanom på extremiteter. Multipla eller ovanliga 
lokalisationer av portvaktskörtel/-körtlar kunde inte identifieras som störfaktorer i 
förhållandet mellan melanom på bålen och reducerad patientöverlevnad (studie I). Melanom 
med intermittenta UV-exponeringsmönster, klassificerade enligt detaljerad anatomisk 
lokalisation av den primära tumören, var associerade med en högre incidensökning från 
1970- till 2000-talet i Stockholm-Gotlandsregionen jämfört med lokalisationer med kroniskt 
UV-exponeringsmönster (studie II). Anatomiska lokalisationer med höggradigt intermittenta 
UV-exponeringsmönster och lokalisationer med låg synlighet för ögat vid självundersökning 
av huden var associerade med minskad patientöverlevnad, jämfört med kroniskt UV-
exponerade och väl synliga lokalisationer (studie III). Intermittent UV-exponerade 
lokalisationer var associerade med BRAF-mutationer, och kroniskt UV-exponerade 
lokalisationer med NRAS-mutationer (studie IV). 
Slutsats: Primära tumörlokalisationer med intermittenta UV-exponeringsmönster förefaller 
relaterade till incidensökningen såväl som minskad patientöverlevnad och genetiska BRAF-
mutationer vid hudmelanom, medan lokalisationer som tilldelas kroniska UVR-
exponeringsmönster bidrar mindre till incidensökningen, är prognostiskt mer fördelaktiga och 
övervägande uppvisar NRAS-mutationer. Multipla eller ovanliga lokalisationer av 
portvaktskörtel/-körtlar förklarar inte den sämre överlevnaden hos patienter med melanom på 
bålen. 
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